Fig. 7. In vivo antitumor effects in HeLa-cell-derived tumor xenograft model.
a Schematic illustration of anticancer therapy for HeLa primary tumors. Note that mice in the groups with the involvement of light irradiation underwent treatment of irradiation (980 nm, 1.0 W/cm2, 5 min) twice, at 8 h and 32 h, respectively, after a single intravenous administration. b Tumor growth curves of different treatments over 55 days (n = 6). c Survival curves of tumor-bearing mice treated with different groups. d Fluorescence imaging of tumor pH value in different groups by using SNARF®-1 and corresponding quantification analysis. The color gradient represents the range from the minimum mean fluorescence intensity (530) to the maximum fluorescence intensity (1680). e The analysis of calcium influx in tumors with different treatments by using flow cytometry and corresponding analysis. f Two-photon fluorescence imaging and corresponding fluorescence intensity analysis of ROS in tumors in different treatments by using DCFH-DA. g Immunohistochemical staining images and further quantitative analysis of UCP 2 in tumor tissue for indicating the mitochondrial damage. h Hematoxylin and eosin (H&E) staining images of tumors in different groups and corresponding quantitative analysis for tumor cells. Data in (d–h) were represented as mean values ± SD, n = 6 biologically independent samples in (b, c), n = 3 biologically independent samples in (d–h). A representative image of three biologically independent samples from each group is shown in (d–h). P values were calculated by the one-way ANOVA in (d–h). P value was calculated by the Log-rank test in (b).